THERAMETRICS HOLDING AG (SIX: TMX) TODAY ANNOUNCES ITS INTENTION TO EXECUTE A CAPITAL INCREASE OUT OF THE EXISTING AUTHORIZED SHARE CAPITAL

Stans, Switzerland, December 10, 2013 - THERAMetrics holding AG (the "Company" - SIX: TMX) today announces its intention to execute a capital increase out of the existing authorized share capital, which shall occur as a private placement to selected investors, by issuing up to 70 million new listed registered shares with a nominal value of CHF 0.01 each. The issue price shall be CHF 0.11 per share. The capital increase shall be executed and the new registered shares listed and issued until 31 March 2014. In this respect, Fin Posillipo S.p.A., one of the Company's main shareholders has confirmed that it will participate in the capital increase and subscribe 30 million new registered shares. Since the capital increase shall occur as a private placement, the subscription rights of the existing shareholders will be excluded and allocated to a circle of selected investors. About THERAMetrics THERAMetrics holding AG is a tech-based Contract Research & Development Organisation dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX) and located in Stans (Switzerland). For further information please contact: THERAMetrics holding AG Investor and External Relations Tel.: +41 79 285 37 81 [email protected] www.therametrics.com

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.